scholarly journals Antiviral Activity of Specific siRNA against Hemagglutinin and Neuraminidase of Influenza Virus H1N1 in MDCK Cell Culture

2016 ◽  
Vol 3 (1) ◽  
Author(s):  
Hamid Reza Mollaei
Keyword(s):  
Cell Culture ◽  
Influenza Virus ◽  
Antiviral Activity ◽  
Mdck Cell ◽  
Virus H1n1

scholarly journals Synthesis and Antiviral Activity of Quercetin Brominated Derivatives

2015 ◽  
Vol 10 (9) ◽  
pp. 1934578X1501000 ◽  
Author(s):  
Elza Karimova ◽  
Lidia Baltina ◽  
Leonid Spirikhin ◽  
Tagir Gabbasov ◽  
Yana Orshanskaya ◽  
...  
Keyword(s):  
Cell Culture ◽  
Influenza Virus ◽  
Acetic Acid ◽  
Antiviral Activity ◽  
Pandemic Influenza ◽  
Mdck Cell ◽  
Inhibitory Activity ◽  
Glacial Acetic Acid ◽  
Absolute Ethanol ◽  
Influenza Virus A

Reaction of quercetin (QR) (1) with bromine under various conditions was studied. Interaction of QR with 2–3 equiv. of bromine in glacial acetic acid at 35–40°C for 2–4 h and 20–22°C for 24 h led to the formation of QR 6,8-dibromide (2) (52–54% yields, 96–98% purity by HPLC). Interaction of QR with 2–5 equiv. bromine in absolute ethanol at 0–5°C and 20–22°C for 24 h led to the formation of 3- O-ethyl-QR-2,3,6,8,5′-pentabromide (3) (95–97% purity by HPLC) the output of which depends on the quantity of bromine. It was shown in MDCK cell culture that compound 2 exhibits a moderate inhibitory activity against pandemic influenza virus A/H1N1/pdm09 (EC50 6.0 μg/mL, CTD50 97.7 μg/mL, SI 16). Compound 3 was inactive.

scholarly journals Antiviral Activity of Fritillaria thunbergii Extract against Human Influenza Virus H1N1 (PR8) In Vitro, In Ovo and In Vivo

2020 ◽  
Vol 30 (2) ◽  
pp. 172-177 ◽  
Author(s):  
Minjee Kim ◽  
Dinh-Van Nguyen ◽  
Yoonki Heo ◽  
Ki Hoon Park ◽  
Hyun-Dong Paik ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Antiviral Activity ◽  
Virus H1n1 ◽  
Human Influenza ◽  
In Ovo ◽  
Human Influenza Virus

scholarly journals #Nitrosocarbonyls 1: Antiviral Activity ofN-(4-Hydroxycyclohex-2-en-1-yl)quinoline-2-carboxamide against the Influenza A Virus H1N1

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Dalya Al-Saad ◽  
Misal Giuseppe Memeo ◽  
Paolo Quadrelli
Keyword(s):  
Influenza Virus ◽  
Antiviral Activity ◽  
Small Molecules ◽  
Influenza A ◽  
Nucleoside Analogues ◽  
Virus H1n1 ◽  
Antiviral Activities ◽  
Synthetic Approaches ◽  
Carbocyclic Nucleoside

Influenza virus flu A H1N1 still remains a target for its inhibition with small molecules. Fleeting nitrosocarbonyl intermediates are at work in a short-cut synthesis of carbocyclic nucleoside analogues. The strategy of the synthetic approaches is presented along with thein vitroantiviral tests. The nucleoside derivatives were tested for their inhibitory activity against a variety of viruses. Promising antiviral activities were found for specific compounds in the case of flu A H1N1.

scholarly journals Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro

2021 ◽  
Author(s):  
Valeria Cagno1 ◽  
Chiara Medaglia ◽  
Andreas Cerny ◽  
Thomas Cerny ◽  
Arnaud Zwygart ◽  
...  
Keyword(s):  
Methylene Blue ◽  
Influenza Virus ◽  
Antiviral Activity ◽  
Uv Light ◽  
H1n1 Influenza ◽  
European Medicines Agency ◽  
Virus H1n1 ◽  
Therapeutic Activity ◽  
Virucidal Activity

Abstract Methylene blue is an FDA (food and drug administration) and EMA (european medicines agency) approved drug with an excellent safety profile. It displays broad-spectrum virucidal activity in the presence of UV light and has been shown to be effective in inactivating various viruses in blood products prior to transfusions. In addition, its use has been validated for methemoglobinemia and malaria treatment. In this study, we first evaluated the virucidal activity of methylene blue against Influenza Virus H1N1 upon different incubation times and in the presence or absence of light activation, and then against SARS-CoV-2. We further assessed the therapeutic activity of methylene blue by administering it to cells previously infected with SARS-CoV-2. Finally, we examined the effect of co-administration of the drug together with immune serum. Our findings reveal that methylene blue displays virucidal preventive or therapeutic activity against Influenza Virus H1N1 and SARS-CoV-2 at low micromolar concentrations and in the absence of UV activation. We also confirm that MB antiviral activity is based on several mechanisms of action as the degradation of genomic RNA is only observed in the presence of light and after long exposure. Our work supports the interest of testing methylene blue in clinical studies to confirm a preventive or therapeutic efficacy against both Influenza Virus H1N1 and SARS-CoV-2 infections.

Impact of cultivation conditions onN-glycosylation of influenza virus a hemagglutinin produced in MDCK cell culture

2013 ◽  
Vol 110 (6) ◽  
pp. 1691-1703 ◽  
Author(s):  
Jana Verena Rödig ◽  
Erdmann Rapp ◽  
Jana Bohne ◽  
Michael Kampe ◽  
Helene Kaffka ◽  
...  
Keyword(s):  
Cell Culture ◽  
Influenza Virus ◽  
Mdck Cell ◽  
Cultivation Conditions ◽  
Influenza Virus A

scholarly journals An MDCK Cell Culture-Derived Formalin-Inactivated Influenza Virus Whole-Virion Vaccine from an Influenza Virus Library Confers Cross-Protective Immunity by Intranasal Administration in Mice

2013 ◽  
Vol 20 (7) ◽  
pp. 998-1007 ◽  
Author(s):  
Ahmad M. Haredy ◽  
Nobuyuki Takenaka ◽  
Hiroshi Yamada ◽  
Yoshihiro Sakoda ◽  
Masatoshi Okamatsu ◽  
...  
Keyword(s):  
Cell Culture ◽  
Influenza Virus ◽  
Pandemic Influenza ◽  
Mdck Cell ◽  
Intranasal Administration ◽  
Influenza Viruses ◽  
Production Model ◽  
Vaccine Production ◽  
Intranasal Immunization ◽  
Homologous Virus

ABSTRACTIt is currently impossible to predict the next pandemic influenza virus strain. We have thus established a library of influenza viruses of all hemagglutinin and neuraminidase subtypes and their genes. In this article, we examine the applicability of a rapid production model for the preparation of vaccines against emerging pandemic influenza viruses. This procedure utilizes the influenza virus library, cell culture-based vaccine production, and intranasal administration to induce a cross-protective immune response. First, an influenza virus reassortant from the library, A/duck/Hokkaido/Vac-3/2007 (H5N1), was passaged 22 times (P22) in Madin-Darby canine kidney (MDCK) cells. The P22 virus had a titer of >2 ×108PFU/ml, which was 40 times that of the original strain, with 4 point mutations, which altered amino acids in the deduced protein sequences encoded by the PB2 and PA genes. We then produced a formalin-inactivated whole-virion vaccine from the MDCK cell-cultured A/duck/Hokkaido/Vac-3/2007 (H5N1) P22 virus. Intranasal immunization of mice with this vaccine protected them against challenges with lethal influenza viruses of homologous and heterologous subtypes. We further demonstrated that intranasal immunization with the vaccine induced cross-reactive neutralizing antibody responses against the homotypic H5N1 influenza virus and its antigenic variants and cross-reactive cell-mediated immune responses to the homologous virus, its variants within a subtype, and even an influenza virus of a different subtype. These results indicate that a rapid model for emergency vaccine production may be effective for producing the next generation of pandemic influenza virus vaccines.

scholarly journals Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Valeria Cagno ◽  
Chiara Medaglia ◽  
Andreas Cerny ◽  
Thomas Cerny ◽  
Arnaud Charles-Antoine Zwygart ◽  
...  
Keyword(s):  
Methylene Blue ◽  
Influenza Virus ◽  
Antiviral Activity ◽  
Uv Light ◽  
Rna Degradation ◽  
European Medicines Agency ◽  
Virus H1n1 ◽  
Therapeutic Activity ◽  
Virucidal Activity

AbstractMethylene blue is an FDA (Food and Drug Administration) and EMA (European Medicines Agency) approved drug with an excellent safety profile. It displays broad-spectrum virucidal activity in the presence of UV light and has been shown to be effective in inactivating various viruses in blood products prior to transfusions. In addition, its use has been validated for methemoglobinemia and malaria treatment. In this study, we first evaluated the virucidal activity of methylene blue against influenza virus H1N1 upon different incubation times and in the presence or absence of light activation, and then against SARS-CoV-2. We further assessed the therapeutic activity of methylene blue by administering it to cells previously infected with SARS-CoV-2. Finally, we examined the effect of co-administration of the drug together with immune serum. Our findings reveal that methylene blue displays virucidal preventive or therapeutic activity against influenza virus H1N1 and SARS-CoV-2 at low micromolar concentrations and in the absence of UV-activation. We also confirm that MB antiviral activity is based on several mechanisms of action as the extent of genomic RNA degradation is higher in presence of light and after long exposure. Our work supports the interest of testing methylene blue in clinical studies to confirm a preventive and/or therapeutic efficacy against both influenza virus H1N1 and SARS-CoV-2 infections.

scholarly journals Highly Efficient Production of an Influenza H9N2 Vaccine Using MDCK Suspension Cells

2020 ◽  
Author(s):  
Yixiao Wu ◽  
Hanjing Jia ◽  
Hanzhang Lai ◽  
Xuping Liu ◽  
Wen-Song Tan
Keyword(s):  
Cell Culture ◽  
Influenza Virus ◽  
Avian Influenza ◽  
Cell Line ◽  
Mdck Cell ◽  
Cell Concentration ◽  
Suspension Cell ◽  
Virus Propagation ◽  
Serum Free ◽  
Mdck Cell Line

Abstract H9N2 subtype avian influenza virus poses a constant threat to the poultry industry and the control of the disease leans upon the use of effective vaccines. As an alternative to the conventional chicken embryonated eggs, animal cell culture could overcome the limitations of egg supplies and upgrade the manufacturing of avian influenza vaccines for poultry. Development of serum-free suspension cell culture could allow even higher virus productivity, where a suspension cell line with good growth and production performance is required. In this work, an adherent MDCK cell line was adapted to suspension growth to cell concentration up to 12 × 106 cells/mL in a serum-free medium in batch cultures. Subsequently, the influenza virus propagation in this MDCK cell line was evaluated and was improved with the medium exchange at time of infection as well as optimization of infection conditions in terms of MOI and cell concentration for infection. Furthermore, various feed strategies were tested in the infection phase for improved virus titer and a maximum hemagglutinin titer of 13 log2 (HAU/50 μL) was obtained using the 1:2 medium dilution strategy. Evaluation of MDCK cell growth and H9N2 virus propagation in the bioreactors with optimized operating conditions showed comparable cell performance and virus yield compared to shake flasks, with a high cell-specific virus yield above 14000 virions/cell. With the purified H9N2 virus harvested from the bioreactor, the MDCK cell-derived vaccine was able to induce high titers of neutralizing antibodies in chickens. Overall, the results demonstrate the promising application of the highly efficient MDCK cell-based production platform for the avian influenza vaccine manufacturing.

Sign in / Sign up

Export Citation Format

Share Document